source
- AstraZeneca outlines restructuring as earnings show cost cuts, while Alnylam slides and Regeneron posts record quarterAstraZeneca said it will redeploy resources through a new restructuring program aimed at cutting costs while staying on track to hit its long‑term revenue goal of $80 billion by 2030. The company h…
- Flagship Pioneering merges three biotech startups to launch AI-driven drugmaker EtceleraFlagship Pioneering announced the creation of Etcelera Therapeutics by merging three of its portfolio companies - Etiome, Cellarity and Empress Therapeutics. The new venture will combine artificia…